济民健康(603222.SH)：上半年净亏损5269.59万元

Core Viewpoint - Jimin Health (603222.SH) reported a significant decline in revenue and incurred losses in the first half of the year, primarily due to external factors and inventory adjustments [1] Financial Performance - The company achieved total operating revenue of 366.44 million yuan, a decrease of 21.30% compared to the same period last year [1] - The medical services segment generated revenue of 168.62 million yuan, down 4.80% year-on-year [1] - The medical device segment reported revenue of 75.10 million yuan, a substantial decline of 47.54% year-on-year [1] - The large-volume infusion segment earned revenue of 121.35 million yuan, reflecting a decrease of 15.50% year-on-year [1] Profitability - The company recorded a net loss attributable to shareholders of 52.70 million yuan and a net loss of 53.20 million yuan after excluding non-recurring gains and losses [1] - The losses were primarily attributed to the impact of U.S. tariff policies and the "He Qinghong stamp incident," which significantly reduced revenue and profits from medical devices [1] - Additionally, the company increased inventory write-down provisions for pre-filled catheter flushing devices and safety syringes based on market sales conditions [1]